MAD2L2 and ovarian cancer: In addition to 53BP1 deficiency, EZH2-meditated epigenetic silencing of MAD2L2 (REV7), a critical factor involved in the 53BP1-dependent NHEJ repair pathway results in resistance to PARPi in ovarian cancer [84].